Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

Item

http://www.wikidata.org/entity/Q36721055

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@ast

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@en

type

Item

label

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@ast

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@en

prefLabel

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@ast

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@en

P1476

Clofarabine Plus Low-Dose Cyta ...... herapy in Elderly AML Patients

@en

P2093

Courtney DiNardo

http://www.w3.org/2001/XMLSchema#string

Guillermo Garcia-Manero

http://www.w3.org/2001/XMLSchema#string

Koichi Takahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.

Management of acute myeloid leukemia in elderly patients.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Age and acute myeloid leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

P304

163-8.e1-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2015.11.016

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26752456

http://www.w3.org/2001/XMLSchema#string

P932

4804759

http://www.w3.org/2001/XMLSchema#string